CSIMarket Company Name, Ticker, Industry, else..
 
Ascendis Pharma A  (NASDAQ: ASND)
 
Price: $263.0400 $15.13 6.103%
Day's High: $268.9800109863281 Week Perf: 3.97 %
Day's Low: $ 247.65 30 Day Perf: 7.84 %
Volume (M): 972,770 52 Wk High: $ 282.15
Volume (M$): $ 0 52 Wk Avg: $225.26
Open: $247.65 52 Wk Low: $186.05



 Market Capitalization (Millions $) 15,942
 Shares Outstanding (Millions) 61
 Employees 100
 Revenues (TTM) (Millions $) 1,342
 Net Income (TTM) (Millions $) -470
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Ascendis Pharma A is a biopharmaceutical company that specializes in developing innovative therapies for rare endocrine diseases. The company is focused on utilizing its proprietary TransCon technology platform to create long-acting prodrug therapies. These therapies aim to improve patients' lives by providing sustained release and targeted treatment options, reducing the burden of frequent dosing and improving efficacy. Ascendis Pharma is known for its strong pipeline of product candidates, including treatments for conditions such as growth hormone deficiency, adult growth hormone deficiency, hypoparathyroidism, and others. The company is committed to advancing scientific research and delivering transformative therapies to patients in need.


   Company Address: Tuborg Boulevard 12 Hellerup 0
   Company Phone Number: 70 22 22 44   Stock Exchange / Ticker: NASDAQ ASND


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADTX   -6.25%    
BOLT        6.42% 
ENSC        8.78% 
GALT        1.8% 
URGN   -6.65%    
VNDA        1.31% 
• View Complete Report
   



Product Service News

Ascendis Pharma Takes a Major Step Forward in the Fight Against Achondroplasia with New Treatment Application

Published Thu, Oct 9 2025 7:18 AM UTC

Ascendis Submits Marketing Authorisation Application for TransCon CNP to Treat Achondroplasia in Children COPENHAGEN, Denmark On October 8, 2025, Ascendis Pharma A/S (Nasdaq: ASND) announced a significant development in the treatment of achondroplasia by submitting a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for its investigational dr...
Clinical Study

Ascendis Pharma Poised for Breakthrough with Key Data Presentations and Record Revenue Growth Ahead of ENDO 2025,

Published Tue, Jul 8 2025 7:44 AM UTC

Uncovering Ascendis Pharma s Promising Data Presentations and Revenue Boom Ahead of ENDO 2025 In a significant development for Ascendis Pharma A/S (Nasdaq: ASND), the company recently announced a lineup of pivotal oral presentations set for ENDO 2025, the annual meeting of the Endocrine Society. Scheduled to take place from July 12-15, 2025, in San Francisco, the conference ...
Clinical Study

Progress and Promise New Insights from the InsiGHTS Trial of Lonapegsomatropin in Turner Syndrome

Published Sun, Dec 29 2024 7:03 PM UTC

The realm of endocrinology is under constant evolution, spearheaded by innovative research and groundbreaking clinical trials. Recently, the InsiGHTS trial made an indelible impact on our understanding and treatment of Turner Syndrome with TransCon hGH (Lonapegsomatropin). Demonstrating significant achievements, this trial has provided fresh insights into the applicability o...
Product Service News

Revolutionizing Care for Hypoparathyroidism YORVIPATH Now Available in the U.S. Offering New Hope to Adults Bat...

Published Thu, Dec 19 2024 1:30 PM UTC

COPENHAGEN, Denmark, Dec. 19, 2024 Ascendis Pharma A/S (Nasdaq: ASND) has announced the impressive milestone of making YORVIPATH (palopegteriparatide) commercially available by prescription in the United States, marking a significant advancement in the treatment landscape for adults suffering from hypoparathyroidism. Approved by the U.S. Food & Drug Administration (FDA), ...
Product Service News

TransCon PTH A Game Changer for Hypoparathyroidism Management - Three-Year Data Illuminate Skeletal Health Benefits

Published Mon, Sep 30 2024 12:30 PM UTC

In a remarkable presentation at the American Society for Bone and Mineral Research (ASBMR) 2024 conference, Ascendis Pharma A/S unveiled compelling three-year data from their ongoing Phase 2 PaTH Forward Trial, revealing the best-in-class potential of TransCon PTH (palopegteriparatide) for the treatment of hypoparathyroidism in adults. This data not only illustrates the rege...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 11.88
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.58
Working Capital Ratio 1.04
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -3.77 $
Revenues (TTM) 22.14 $
Cash Flow (TTM) -
Cash 11.42 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 13,417,521
Net Income per Employee (TTM) -4,703,857
Receivable Turnover Ratio (TTM) 8.48
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) 0.92

Profitability Ratios Current
Gross Margin (MRQ) 86.82 %
Operating Margin (MRQ) -18.92 %
Net Margin (MRQ) -31.67 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Ascendis Pharma A's Segments
United States    75.87 % of total Revenue
Europe    16.79 % of total Revenue
Rest of World    7.33 % of total Revenue
Denmark    1.79 % of total Revenue
YORVIPATH    66.3 % of total Revenue
SKYTROFA    28.63 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.